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In France, primary lung cancer (all types combined) is the leading
cause of cancer mortality in men, and the third in women, after
breast and colorectal cancer. In 1995, lung cancer was responsible
for 23.5% of cancer deaths in men and 6.4% in women. The
incidence of lung cancer is higher in men than in women, and the
mortality rate is nine times higher in men than in women. The lung
cancer mortality rate is constantly increasing in France, particu-
larly in the north of the country. The increase in incidence between
1975 and 1995 was more marked in women. In France, the 5-year
survival rates (11.5% for men and 16% for women) are among the
highest in Europe.
OBJECTIVES
The objective of these recommendations is to define, on the basis
of a critical appraisal of the best available evidence and expert
agreement, clinical practice guidelines for the diagnosis and
therapeutic management of patients with stage I–IV non-small-
cell lung cancer. The document does not cover preoperative work-
up. Management of relapsed disease will be covered in a future
document.
Methodology
The general methodology has been previously described (Fervers
et al, 2001). For this particular Standards, Options and Recom-
mendations (SOR), a working group of multidisciplinary experts
was established by the French National Federation of Cancer
Centres (Fe ´de ´ration Nationale de Centres de Lutte Contre le
Cancer: FNCLCC) and the French Lung Society (Socie ´te ´ de
Pneumologie de Langue Franc¸aise: SPLF). A literature search of
Medline
s, Cancerlit
s and The Cochrane Library
s up to October
1999 was performed and this was completed with references from
the personal reference database of the members of the working
group.
After selection and critical appraisal of this literature, the
working group defined the ‘Standards’, ‘Options’ and ‘Recommen-
dations’ (SORs) for the diagnostic and therapeutic management of
patients with non-small-cell lung carcinoma based on a synthesis
of the best available evidence.
‘Standards’ identify clinical situations for which there exist
strong indications or contra-indications for a particular interven-
tion and ‘Options’ identify situations for which there are several
alternatives, none of which have shown clear superiority over the
others (Table 1). In any SOR, there can be several ‘Options’ for a
given clinical situation. ‘Recommendations’ enable the ‘Options’t o
be weighted according to the available evidence. Several interven-
tions can be recommended for the same clinical situation, so that
clinicians can make a choice according to specific clinical
parameters, for example, local circumstances, skills, equipment,
resources and patient preferences. Adapting the SORs to a local
situation is possible if the reason for the choice is sufficiently
transparent and this is crucial for successful implementation.
Inclusion of patients in clinical trials is an appropriate form of
patient management in oncology and is recommended frequently
within the SORs, particularly in situations where the evidence is
too weak to support an intervention.
The type of evidence underlying any ‘Standard’, ‘Option’o r
‘Recommendation’ is indicated using a classification developed by
the FNCLCC based on previously published models. The level of
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reviewed, but also on the concordance of the results (Table 2).
When no clear scientific evidence exists, judgement is made
according to the professional experience and consensus of the
expert group (‘expert agreement’).
The document containing the SORs for the diagnostic and
therapeutic management of patients with non-small-cell lung
carcinoma was then peer-reviewed by independent experts. These
SORs will be updated when new evidence becomes available or if
there is a new consensus among the experts.
This summary report has been produced from the integral
report that was validated in August 2000, and published as a
monography (Depierre et al, 2002), a summary of version
(Depierre et al, 2003) and on the web site of the FNCLCC
(http://www.fnclcc.fr).
IDENTIFICATION OF POSSIBLE OCCUPATIONAL
RISK FACTORS FOR PRIMARY LUNG CANCER
All patients with lung cancer should have a specialist consultation
to identify any possible occupational cause. If an occupational
cause is identified, a declaration of occupational illness should be
made (recommendation, expert agreement).
SMOKING IN PATIENTS WITH LUNG CANCER
In patients treated for lung cancer, active smoking is an operative
and postoperative risk factor and is very likely to increase the risk
of a second lung, head and neck or oesophageal cancer. Patients
receiving curative treatment for lung cancer should be specifically
targeted with smoking cessation strategies (recommendation, level
of evidence: B).
SMOKING CESSATION STRATEGIES
Efficacy of nicotine substitutes
In patients with a nicotine dependence, chewing gum and skin
patches have been shown to be efficacious for stopping smoking
(standard, level of evidence: A).
Efficacy of behavioural treatments
Group therapy has been shown to be more efficacious than no
intervention or minimal contact (standard, level of evidence: A),
but it is no better than other behavioural interventions (standard,
level of evidence: B1).
Efficacy of acupuncture, hypnosis and homeopathy
There is no evidence to suggest that acupuncture, hypnosis or
homeopathy are efficacious in stopping smoking (level of evidence:
A).
Efficacy of training health professionals
Training health professionals to give advice, in isolation, is
probably not an efficacious strategy for smoking cessation (level
of evidence: A).
CHEMOPREVENTION OF LUNG CANCERS
No chemopreventive agent has been shown to be efficacious in the
general population, in smokers, in workers exposed to occupa-
tional carcinogens or in patients who have undergone surgery for a
previous tobacco-related cancer (standard, level of evidence: B1).
Beta-carotene has a deleterious effect on mortality and the risk of
lung cancer (level of evidence: B1). Chemopreventive agents
should not be offered to patients who smoke and who have lung
cancer, to patients exposed to chemical carcinogens, or to patients
treated for tobacco-related cancers, who have a good prognosis
(standard).
The only efficacious prevention is an anti-tobacco campaign
aimed at the general population, patients exposed to carcinogens,
and patients treated for a previous lung or head and neck cancer
(recommendation, expert agreement).
SCREENING FOR LUNG CANCERS
Cytological investigation of sputum has not been shown to be
useful in screening for lung cancer (standard, level of evidence:
B1). Regular chest X-rays can be performed in smokers and
Table 1 Definition of ‘Standards, Options and Recommendations’
Standards Procedures or treatments that are considered to be of benefit, inappropriate or harmful by unanimous decision, based on
the best available evidence
Options Procedures or treatments that are considered to be of benefit, inappropriate or harmful by a majority, based on
the best available evidence
Recommendations Additional information to enable the available options to be ranked using explicit criteria (e.g., survival, toxicity)
with an indication of the level of evidence
Table 2 Definition of level of evidence
Level A
There exists a high-standard meta-analysis or several high-standard randomised clinical trials that give consistent results
Level B
There exist good quality evidence from randomised trials (BI) or prospective or retrospective studies (B2). The results are consistent when considered together
Level C
The methodology of the available studies is weak or their results are not consistent when considered together
Level D
Either the scientific data does not exist or there is only a series of cases
Expert agreement
The data do not exist for the method concerned, but the experts are unanimous in their judgement
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extent of radiation exposure and the age at which screening
should be initiated have not been determined (option, level of
evidence: B1).
Mass screening cannot be justified, outside the setting of
prospective controlled studies. These trials should assess aspects
that have not been addressed previously, such as the early
identification of certain markers from sputum or the usefulness
of spiral CT scan in screening (recommendation).
IMAGING IN THE DIAGNOSIS OF LUNG CANCER
Diagnostic imaging tests
When possible, a spiral CT scan should be undertaken for
diagnostic imaging as it gives the best image (option, level of
evidence: D). An anterior–posterior and lateral chest X-ray,
performed with a high kilovoltage technique, is essential in the
diagnostic work-up (recommendation). If lung cancer is suspected,
a normal chest X-ray will not be sufficient to exclude the diagnosis
(recommendation). Patients with any suspicion of lung cancer,
despite a normal chest X-ray, should have a thoracic CT scan
(recommendation). If a suspicious lesion is observed on a normal
chest X-ray, a thoracic CT scan is warranted, if treatment, other
than supportive care, is envisaged; a baseline evaluation is
required to assess treatment response; or a transparietal fine
needle biopsy is planned (recommendation).
A CT scan image is not sufficiently specific to confirm the
diagnosis (recommendation).
Positron emission tomography (PET scanning) in
diagnosis
Surgery is not recommended if the lung lesion measures less than
10mm and if there is no fluoro-2-deoxy-D-glucose (FDG) uptake.
Clinical and radiological surveillance should be undertaken for
4–6 months to ensure that the lesion does not increase in size. The
upper limit of nodule size warranting this approach is not known,
but it is estimated to be perhaps up to 40mm. This policy of
surveillance is particularly appropriate to minimise any unneces-
sary invasive active investigation of a nodule (recommendation,
expert agreement).
DIAGNOSTIC LUNG ENDOSCOPY
Sputum cytology is not specific for lung cancer, therefore
histological confirmation should be obtained (standard).
Bronchoscopy
The investigation should be performed under general anaesthetic,
particularly if several samples are to be taken and the procedure is
likely to be prolonged (option). Disposable bronchoscopes and
biopsy clamps can be used (option). If a distal tumour is
suspected, distal samples can be taken using an intensifying
screen, to avoid the need to perform a transparietal fine needle
biopsy (option). If the nodule is peripheral and smaller than 2cm,
the sample should be taken via a transparietal fine needle biopsy
(option).
In patients with haemoptysis, emergency bronchoscopy can
localise the bleeding. If there is no urgency and if abnormal lesions
are visible on a chest X-ray, CT scan images can help to localise the
area prior to bronchoscopy (option).
Routine haematological and biochemical tests should not
replace history taking and clinical examination (recommendation).
It is not necessary to perform this work-up except in high-risk
patients (recommendation, expert agreement). Bronchoscopy is
recommended if lung cancer is suspected and if treatment other
than symptomatic treatment is envisaged (recommendation).
In patients with a proximal tumour, several samples should be
taken, using different methods (recommendation, expert agree-
ment). For patients with a distal tumour, at least one fine needle
aspirate should be taken for cytology (recommendation, expert
agreement).
THORACIC TRANSPARIETAL NEEDLE BIOPSY
If the lesion is thought to be a benign tumour, a trucut biopsy
needle is preferable for obtaining larger tissue samples, which will
be easier to interpret (option, level of evidence: B2).
If the CT scan results are suggestive of lung cancer, and there is
no other simple method for obtaining a histological diagnosis, or if
the other methods have failed, a transparietal needle biopsy is
recommended (recommendation).
For patients with a CT scan strongly suggestive of lung cancer in
whom transparietal needle biopsy is contra-indicated, and surgery
is feasible, exploratory surgery can be considered, even in the
absence of histological diagnosis (recommendation, expert agree-
ment).
PROGNOSTIC FACTORS FOR SURVIVAL FOR
PATIENTS WITH NON-SMALL-CELL LUNG CANCER
Operable patients
Among the numerous variables studied, only the TNM (Figure 1)
staging method has been found to have a prognostic value
consistently (level of evidence: B2).
Inoperable patients
In inoperable patients, weight loss, performance status, gender,
presence of metastases, high LDH concentrations, elevated white
blood cell count and anaemia have been identified as prognostic
factors in numerous studies (level of evidence: B2).
The value of new biological prognostic factors should be
assessed in prospective studies (recommendation).
MANAGEMENT OF PROXIMAL SUPERFICIAL LUNG
CANCERS AND PRECANCEROUS LESIONS:
PROBLEMS FOR DIAGNOSIS OF RADIO-OCCULT
CANCERS (FIGURE 2)
Diagnostic work-up investigations
In patients with positive sputum cytology, bronchoscopy, CT
scanning and specialised investigations to exclude a head and neck
cancer should be performed (standard). In patients with negative
results from initial tests of sputum cytology, bronchoscopy, with
multiple samples, bronchoscopy, with autofluorescence, or regular
surveillance using lung fibroscopy and CT scanning can be
envisaged (option).
In high-risk patients, heavy smokers, those exposed to carcino-
gens or with previous lung or digestive tract cancers, broncho-
scopy, with autofluorescence, can be performed (option).
Management of carcinoma in situ (CIS)
Unlike other precancerous lesions, CIS should be eradicated
because of the likely progression and low rate of spontaneous
regression (standard, level of evidence: B2). Following treatment
for a CIS, routine follow-up with bronchoscopy is indicated
(standard). Local endobronchial treatment should be undertaken
SOR for management of lung carcinoma patients
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frequency of secondary metachronous lesions (recommendation).
Management of severe dysplasia
Patients with severe dysplasia should only be treated locally if the
bronchial tree is involved. Bronchoscopic follow-up can be
performed 2 months later (recommendation).
Management of low-grade lesions
Low-grade lesions should not be treated and the patient should be
advised to stop smoking (standard). No recommendations can be
established for the follow-up of moderate dysplasia, but broncho-
scopy after about 1 year is recommended (recommendation).
Management of radio-occult cancer (Figure 3)
An invasive radio-occult cancer should be treated in the same way
as an invasive cancer (standard). If the CT scan shows an
obstructive lesion or is suspicious for peribronchial nodal
invasion, a lobectomy should be performed (standard). If a spiral
CT scan does not show node invasion, local treatment (photo-
dynamic therapy, brachytherapy or segmentectomy) is appropriate
for lesions visible on bronchoscopy (option). This applies to
lesions that extend less than 10mm into the bronchial tree when
they are situated in one of the segmental bronchi, and less than
7mm when they are situated more distally. Segmentectomy with
dissection of the lobar, interlobar and segmental nodes can be
undertaken for lesions localised beyond the bronchoscopic field of
vision or for those larger than 10mm, if the excision margins are
clear and the resected nodes are negative (option).
Patients with lesions that are visible on bronchoscopy and
extend less than 10mm into the bronchial tree (when they are
situated in one of the segmental bronchi), and less than 7mm
(when they are situated more distally), should be included in
randomised clinical trials assessing the benefits of new techniques.
This applies as long as spiral CT scan does not show node invasion
(recommendation).
INTERVENTIONAL BRONCHOSCOPY
Endobronchial techniques are useful for symptomatic proximal
obstructions (option). For patients with major extrinsic compres-
sion of the bronchial lumen, an air-tight endoluminal prosthesis
can be fitted (option). Endobronchial treatment for obstructed
airways is indicated for patients with symptomatic proximal
obstructions prior to specific medical treatment (recommenda-
tion).
Curative bronchoscopic treatment is recommended for carcino-
ma in situ. This includes, in order of preference: cryotherapy,
photochemotherapy, thermocoagulation and luminal endo-bra-
chytherapy (recommendation).
WHO HISTOLOGICAL CLASSIFICATION
The 1999 WHO classification for lung carcinomas, which is based
on standard light microscopic criteria, should be used (standard).
The diagnosis of a squamous cell carcinoma is based on the
finding of intercellular junctions and keratinisation. The diagnosis
of a nonbronchioalveolar adenocarcinoma is based on the finding
of glandular and/or papillary structures or on the immunohisto-
chemical detection of mucin (standard). The diagnosis of
adenosquamous carcinoma is based on the finding of at least a
5% glandular component, identifiable by light microscopy
(recommendation, level of evidence: D).
A carcinoma with a bronchioalveolar structure that has a
fibrotic zone should be classified as a ‘classical’ adenocarcinoma
(recommendation).
Non-small-cell lung cancer after 
pretherapeutic work-up
Standard:
TNM classification
Stage?
Stage 0
Figure 3

Stages IA-B
and IIA-B
Figure 7
Stage IIIA
Figure 8
 
Stage IIIB
Figure 9
Stage IV
Figure 11
 
Figure 1 Classification by stage
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routinely for large-cell carcinoma unless they present with
neuroendocrine morphology (recommendation, expert agree-
ment). For the diagnosis of neuroendocrine tumours, the number
of mitoses per mm
2 should be stated (the area being calculated
according to microscopic settings) (recommendation, expert
Positive cytology and normal X-ray
Standard:
bronchial fibroscopy
Positive Negative
Results?
Cancer diagnosed Cytology:
squamous cell carcinoma 
Cytology:
adenocarcinoma
Standard:
occupational disease
consultation
Pretherapeutic
locoregional work-up
Figure 4
 
Repeat
investigations
Figure 2
Negative Positive
Results?
Standards:
   thoracic CT scan
   head and neck investigation
   oesophageal fibroscopy
Option:
bronchial fibroscopy with auto
fluorescence
Standards:
   thoracic CT scan
   deep samples
   head and neck
   investigation
   oesophageal fibroscopy
Figure 2 Radio-occult lung cancers
SOR for management of lung carcinoma patients
A Depierre et al
S39
British Journal of Cancer (2003) 89(Suppl 1), S35–S49 & 2003 FNCLCCagreement). An immunohistochemical study is recommended for
fusiform-cell carcinomas with no obvious epithelial differentiation
(recommendation, expert agreement).
PROGNOSTIC VALUE OF ONCOGENES AND TUMOUR
SUPPRESSOR GENES
There is no clinically useful prognostic value for the various
oncogenes and tumour suppressor genes (p53, bcl-2, Ki-ras,
c-erbB-2, Rb, p16) that have been identified in patients with non-
small-cell lung cancer (standard).
Large prospective multicentre studies are necessary to assess the
prognostic value of oncogenes and tumour suppressor genes, with
the involvement of a multidisciplinary working group (recom-
mendation).
USE OF SERUM TUMOUR MARKERS
The use of serum tumour markers in the management of non-
small-cell lung cancer is not justified (standard).
MEDIASTINAL LYMPH NODE STAGING (FIGURE 4)
All patients should have at least a thoracic CT scan (standard).
MRI does not give better results than CT, but it can be undertaken
as an alternative in patients with a formal contra-indication to
iodinated contrast media (standard).
A mediastinal lymph node is suspicious when its smallest
diameter is greater than 10mm (standard). Mediastinal lymph
node samples should not be taken, outside the setting of a clinical
trial, for nodes smaller than 10mm. If there is evidence of
adenopathy greater than 10mm, and if positive results will modify
the treatment plan, further investigations can be undertaken
(option).
Transbronchial and ultrasound-guided trans-oesophageal per-
cutaneous fine-needle aspiration can be undertaken in patients for
whom the demonstration of lymph node invasion would signifi-
cantly modify the treatment plan and therefore, their chance of
survival. In these patients, mediastinoscopy should be performed,
or when other techniques have given negative results (option).
The best quality result is obtained with an injection of contrast
media (recommendation, expert agreement), using modern
equipment (recommendation, level of evidence: A) using contig-
uous sections of 8 and 5mm in the hilar region, or spiral CT
machines (recommendation, expert agreement).
INITIAL WORK-UP FOR DETECTING EXTRA-THOR-
ACIC INVOLVEMENT (FIGURES 5 AND 6)
Basic work-up should be undertaken prior to any new course of
therapy. The work-up should include a liver ultrasound and a
thoracic CT scan that includes the adrenal glands (standard).
Patients with pain in the axial skeleton should undergo MRI as a
first-line investigation. Standard radiography with CT scan or MR
(with cross-sectional imaging, if necessary) should be performed
in patients with bone pain elsewhere (standard). Other investiga-
tions (liver CT scan and MRI, brain MRI) should only be
performed in addition to the investigations above, in certain
situations (standard).
Yes No
Radio-occult non-small-cell lung cancer
stage 0 or TX, T0, Tis
Patient fit for
surgery?
Standard:
surgery
Option:
endo-bronchial treatment
Figure 3 Radio-occult stage 0 or TX, T0, Tis tumours
Diagnosis of a non-small-cell cancer, 
stage T1-3 N0-1
Standard:
thoracic CT scan
Option:
MRI if formal contra-indication for CT
contrast media
Yes  No Mediastinal node with the
smallest diameter greater
than 10 mm
Option:
   transbronchial needle biopsy
   transoesophageal needle biopsy with 
   ultrasound control
   mediastinoscopy
   positron emission tomography

Extra-thoracic pre-
therapeutic work-up
Figures 5 and 6
Figure 4 Pretherapeutic work-up for mediastinal node involvement
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stage of disease and symptoms (option). When available, brain
MRI can be the first-line investigation (option). MRI is recom-
mended for patients with a single brain metastasis (recommenda-
tion, expert agreement). Morphological detection of a single
metastasis (brain, adrenal gland, etc.) requires histological
confirmation, if this is the only contra-indication for chest surgery
(recommendation, expert agreement).
Clinical studies should be performed to assess the impact of
adrenal gland involvement, to compare brain CT scan and MRI,
and to evaluate the cost-efficacy ratio for PET scanning
(recommendation).
Diagnosis of non-small-cell lung cancer, stage T1-3 N0-1
Yes No
Curative treatment?
Standards:
   brain CT scan with contrast enhancement
   liver ultrasound
   CT scan to exclude adrenal gland involvement
   no indication for serum tumour marker assay
Option:
brain MRI
Standard:
no work-up other than
thoracic in the absence of
suggestive symptoms
No Yes Painful bone
symptoms?
Localisation of
bone pain
Vertebral Nonvertebral
Standards:
   MRI
   serum calcium and
   alkaline phosphatase
   assays
Options:
   bone scan
   X-ray of the painful bone
   serum calcium and alkaline
   phosphatase assays
Classification by
stage
Figure 1

Figure 5 Pretherapeutic work-up for extra-thoracic involvement
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alternative to the current standard work-up (option).
Bone scintigraphy has limited utility because of its lack of
specificity (standard).
Tumour markers have no value in this work-up (standard).
GOOD PRACTICE GUIDELINES FOR SURGICAL
TREATMENT
Surgical excision of lung cancers should be performed by an
experienced chest surgeon, who operates regularly (standard, level
Standards:
   brain CT scan with contrast 
   liver ultrasound
   CT scan to exclude adrenal gland involvement
   no indication for serum tumour marker assay
Option:
brain MRI
Diagnosis of non-small-cell lung cancer stages, T1-3 N2-3,
T4 N0-3
Locoregional
treatment?
Yes
Yes
No
No
Standard:
no work-up in the absence of
suggestive symptoms
Painful bone
symptoms?
Localisation of
bone pain
Vertebral Nonvertebral
Standards:
   MRI
   serum calcium and
   alkaline phosphatase
   assays
Options:
   bone scan
   X-ray of the painful bone
   serum calcium and alkaline
   phosphatase assays
Classification
by stage
Figure 1

Figure 6 Pre-therapeutic work-up for extra-thoracic involvement
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manage postoperative complications (standard). The decision to
operate or not should be made after a multidisciplinary consulta-
tion within the institution (standard). The surgical and patholo-
gical reports should reflect the quality of the treatment and should
be standardised (standard).
GOOD PRACTICE GUIDELINES FOR RADIOTHERAPY
Good practice guidelines for external-beam radiotherapy
Radiotherapy should conform to the guidelines of the Interna-
tional Commission on Radiation Units (ICRU) reports 29, 50 and
62, and the recommendations of quality assurance programmes,
such as those proposed by the French Society of Oncological
Radiotherapy and the French Society of Hospital Physicians
(standard).
Thoracic radiotherapy should be performed using a high-energy
linear photon accelerator (standard). The weekly dose, following
classical application, should not exceed 10Gy (recommendation).
Split-course radiotherapy should only be performed as a palliative
treatment (recommendation).
The use of recognised and validated classification systems, such
as the RTOG/EORTC system, is essential for reporting treatment
toxicity (recommendation).
Good practice guidelines for endobronchial brachytherapy
The dose for endobronchial brachytherapy with a single catheter
should be specified in the central plane at 1cm from the source
(standard, expert agreement). The efficacy of endobronchial
brachytherapy has not yet been established.
SURGICAL TREATMENT (FIGURE 7)
Basis of surgical treatment
Surgical treatment of lung cancer should involve excision of the
diseased lobe or the lung itself and ipsilateral mediastinal node
dissection (standard). There is no consensus as to the extent of the
node dissection.
Operative mortality
The operative mortality rate for pneumonectomy should be less
than 6%, and that for lobectomy should be less than 2%
(recommendation).
Limits for certain types of excision
Excision by lobectomy or pneumonectomy with node dissection is
the basis for surgery in lung cancer (standard). Pneumonectomy
carries a higher operative risk, but the results, in terms of cancer
treatment, are better (standard, level of evidence: B2). Exception-
ally, segmental or atypical excision can be undertaken in patients
with respiratory failure or in elderly patients for whom normal
excision is not possible (option).
Lobectomy with bronchoplasty is an alternative treatment to
pneumonectomy in patients with node-negative, small tumours or
those with respiratory failure (option). Simple surveillance is
preferable to radiotherapy in patients who have undergone re-
excision and who have bronchial invasion by an epithelioma in
situ (recommendation, level of evidence: B2). Pneumonectomy,
following neoadjuvant treatment, is probably associated with a
higher risk of morbidity.
Limitations related to tumour extension (Figure 8)
In patients with stage T3 tumours, wide excision is justified for
stage N0 or N1 tumours (standard). In patients with stage T1-T2N0
tumours, a single, isolated operable brain metastasis is a formal
indication for surgery if the patient has no contra-indication for
chest surgery (standard, level of evidence: B2).
Surgery is contra-indicated in patients with stage N3 tumours,
outside the setting of a prospective clinical trial (standard).
Multiple tumour localisations should be used when undertaking
curative surgery (standard). T4N0 tumours can be treated by wide
excision in carefully selected patients (option). There is no
consensus as to the usefulness of pneumonectomy in patients
with stage N1 tumours (option). Radical excision, rather than
nonsurgical treatment, is justifiable for stage N2 tumours
(option).
Surgical limitations related to patient characteristics
In strictly selected patients, age is not an absolute contra-
indication for surgical excision for lung cancer (standard, level
of evidence: B2). A previous malignancy outside the lung is not a
contra-indication for planned curative excision (standard).
Surgery should be the treatment of choice for patients with
metachronous cancers, as for patients with primary lung cancer
(standard, level of evidence: D).
Cancer in a single lung after pneumonectomy can be treated by
conservative resection in patients with the following criteria
(option): initial cancer with a good prognosis (stage I or II), no
metastases detected, no nodal involvement at mediastinoscopy,
good performance status, and absence of cardiovascular disease.
In elderly patients, conservative excision techniques should be
undertaken (lobectomy, segmentectomy) (recommendation). Se-
vere vascular disease should be treated prior to lung surgery
(recommendation). Lung function should be evaluated by VO2max
determination. The threshold for operability is a VO2max of about
15mlkg
1min
1 (recommendation).
POSTOPERATIVE TREATMENT
Postoperative radiotherapy
Radiotherapy is not indicated in patients with stage I and II N0-N1
tumours, if excision was complete (standard, level of evidence: A).
New radiotherapy techniques should be evaluated in patients with
stage III tumours in the setting of a randomised clinical trial to
assess their efficacy (recommendation).
Adjuvant chemotherapy
The efficacy of adjuvant chemotherapy has not been clearly
demonstrated. Adjuvant chemotherapy should only be performed
in the setting of a randomised clinical trial (recommendation).
NEOADJUVANT CHEMOTHERAPY
The need for multidisciplinary consultation is the only standard in
this rapidly changing area (standard). Neoadjuvant chemotherapy
can be given to patients with stage IB, II and IIIA tumours (option,
level of evidence: C).
It is not known whether improving the operability of a tumour
results in improved survival (option). Hence, chemotherapy or
radiochemotherapy should not be routinely undertaken in patients
with stage IIIA tumours, when complete excision of the tumour is
uncertain (option). These patients should be included in
randomised clinical trials (recommendation).
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I AND II TUMOURS
Curative external-beam radiotherapy, with classical fractionation,
is an alternative to surgical excision only in patients with medical
contraindications for surgery or for those who refuse surgery
(standard, level of evidence: C).
Delivering a total dose of more than 60Gy to the tumour mass
can be advantageous if the radiotherapy technique proposed
(directed or dosimetric distribution) takes into consideration the
patient’s respiratory function and does not increase the risk of
severe radiotherapy-induced complications (standard, level of
evidence: C).
Other radiotherapy techniques (modified fractionation, con-
comitant radiochemotherapy, high-dose rate endoluminal bra-
chytherapy alone or in association with external-beam
radiotherapy) should only be undertaken in the setting of a
randomised clinical trial for patients with stage IB or II tumours
(recommendation, level of evidence: D).
External-beam radiotherapy to the primary tumour volume alone,
not including the mediastinum, can be considered in patients with
peripheral stage IA tumours. This treatment should only be
undertaken in patients with proximal stage IA and stage IB tumours
in the setting of a randomised controlled trial, comparing localised
irradiation to the tumour volume with a large field, encompassing
tumour and mediastinum (recommendation, level of evidence: D).
Non-small-cell lung cancer, stages I and II,
T1-2, N0-1
Yes No
Standards:
   radiotherapy
   high-energy linear photon
   accelerator
Patient′s general and functional
condition suitable
for surgery?
Standards:
   surgical excision
   ipsilateral mediastinal dissection
Options:
   widespread dissection
   neoadjuvant chemotherapy
Node
involvement?
pT1-2 N0-N1 ′minimum′
pT1-2 N2
Standard:
no adjuvant
radiotherapy
Standard:
no standard
adjuvant treatment
Figure 7 Stage I and II tumours
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and a safety margin of 1.5–2cm (recommendation, level of
evidence: D).
TREATMENT OF LOCALLY ADVANCED CANCERS
External-beam radiotherapy
When treating locally advanced non-small-cell lung cancers,
external-beam radiotherapy should be of optimal quality and
should deliver a minimum dose of 60Gy with classical fractiona-
tion (standard, level of evidence: B1).
For patients with a reduced life expectancy, this radiotherapy
can be delivered as a split course or in a hypofractionated mode
(option).
Hyperfractionated and accelerated hyperfractionated radiother-
apy should only be performed in the setting of randomised clinical
trials (option).
The efficacy of conformal radiotherapy in the treatment of
locally advanced non-small-cell lung cancer should be assessed in
randomised clinical trials (recommendation).
Radiosensitisation
The combination of weekly chemotherapy (platin-based and
others) with radiotherapy should only be performed in the setting
of a randomised clinical trial (recommendation).
Induction chemotherapy
Patients with locally advanced tumours and a performance status
of 0 or 1 should receive a combination of short sequential
Yes No
Non-small-cell lung cancer, stage IIIA
T?  N?
T3 N1 T1-3 N2
Yes No Standard:
wide excision
Excisable and
operable?
Option:
complete excision and
wide node dissection
complete excision?
Follow-up
after
treatment
Figure 2
 Standard:
external-beam radiotherapy at optimal
dose with classical fractionation
   short-term induction chemotherapy with 
   cisplatin and at least one other drug,
and
   external-beam radiotherapy at optimal dose 
   with classical fractionation
Options:
   radiotherapy alone at the optimal dose
   for patients with short life expectancy, split 
   course or hypofractionated radiotherapy
Standards:
Figure 8 Stage IIIA tumours
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other drug, and conventional radiotherapy (standard, level of
evidence: A).
Concomitant radiotherapy and chemotherapy
It is possible to deliver chemotherapy and radiotherapy concur-
rently (recommendation). Treatment schemas should be evaluated
in the setting of a randomised clinical trial (recommendation).
Surgery
Stage N3 tumours remain a contraindication for classical surgery
(standard). There is no justification for combining radioche-
motherapy (adjuvant or neoadjuvant) with surgery in patients with
stage N3 tumours outside the setting of a randomised clinical trial
(standard).
Surgical excision remains justified in patients with stage N2
cancer because of the good quality of local control obtained
(option). Patients with stage T4-N0 cancer can undergo curative
surgical excision (option).
Management of locally advanced non-small-cell lung
cancers (Figure 9)
The treatment of choice is radiotherapy aimed at local control and/
or improved survival (standard). Surgical excision can be under-
taken in carefully selected patients, particularly those with a T4N0
tumour (option).
External-beam radiotherapy should be of optimal quality (high-
energy 9MV photons, with individualised lead shielding and
Non-small-cell lung cancer, stage IIIB
IIIB
T?, N?
No Yes Pleural effusion of
tumour origin?
T4
N0
N?
N3 
Management of
pleural effusion
Figure 10
Option:
multidisciplinary discussion for
treatment plan comprising
complete excision with
extension to mediastinal
structures
Surgical
Operative contra-indication:
   short-term induction chemotherapy with cisplatin and
   at least one other drug
and
   external-beam radiotherapy at the optimal dose with
   classical fractionation
Options:
   radiotherapy at the optimal dose alone if
   chemotherapy refused
   for patients with short life expectancy, split course or
   hypofractionated radiotherapy
Figure 9 Stage IIIB
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60Gy, with classical fractionation, should be delivered to achieve
local control (standard). Wide surgical excision, associated with
perioperative radiotherapy, gives a survival rate of between 20 and
35% in carefully selected patients with T4N0 tumours, although the
operative mortality is about 10% (standard). Essential surgical
staging, using mediastinoscopy, should provide guidance for the
therapeutic decision-making process (standard).
Radiotherapy, at a dose of 60Gy can be delivered as a split
course with a rest period of 2–4 weeks (option). Hypofractionated
radiotherapy gives a better quality of life for patients with less than
3 months life expectancy (option). Hyperfractionated radiotherapy
does not seem to be more efficacious and has higher toxicity.
Accelerated radiotherapy is an alternative to conventional radio-
therapy for improving local control, but results in greater toxicity
thus excluding combination with chemotherapy (option).
The efficacy of conformal radiotherapy in the treatment of
locally advanced non-small-cell lung cancer should be assessed in
a randomised clinical trial (option). The combination of a weekly
injection of cisplatin with split course radiotherapy can improve
local control and even improve survival, but results in significant
gastrointestinal toxicity (option). The sequential combination of
induction chemotherapy (containing cisplatin and at least one
other drug) with conventional radiotherapy can reduce the rate of
metastases and improve short-term survival, particularly in
patients with a good prognosis (option). Induction chemotherapy
alone or in combination with moderate dose radiotherapy (40–
45Gy), prior to complex surgical excision, may be indicated in
selected patients with stage IIIA or IIIB cancers (i.e., those with
potentially excisable tumours, and a good performance status)
(option). Induction treatment can increase the risk of acute
respiratory distress syndrome (ARDS) after pneumonectomy.
These complex and toxic treatments should be undertaken,
whenever possible, in the setting of a randomised clinical trial
(option).
MANAGEMENT OF PLEURAL EFFUSION (FIGURES 9
AND 10)
Diagnosis of pleural effusion
In patients with localised tumours, pleural effusion should be
investigated (via cytology or histological sampling) to determine
whether it is neoplastic or benign in origin (standard). The
investigation should be performed by an experienced cytopathol-
ogist (standard). If locoregional treatment is not indicated, it is not
necessary to perform thoracoscopy (recommendation, expert
agreement).
Treatment of pleural effusion
Thoracoscopy with talc pleurodesis is the standard treatment for
patients with malignant pleural effusion recurring in a nontrapped
lung (standard, level of evidence: B1). When thoracoscopy with
talc pleurodesis cannot be performed, the following treatments can
be considered (options):
 intrapleural instillation of a talc suspension;
 intrapleural instillation of bleomycin;
 intrapleural instillation of tetracyclines.
TREATMENT OF METASTATIC CANCERS (FIGURE 11)
Single metastasis
Excision of the primary tumour and the metastasis can be
undertaken in patients with operable non-small-cell lung cancers
and a single brain metastasis (standard, level of evidence: C) or
adrenal gland metastasis (standard, level of evidence: D).
Role of chemotherapy
Chemotherapy containing cisplatin should be offered to patients
with stage IV non-small-cell lung cancer and a performance status
of 0 or 1 (standard, level of evidence: A).
Chemotherapy in elderly patients
Chemotherapy without cisplatin can be considered in elderly
patients (option, level of evidence: C).
Non-small-cell lung cancer and pleural
effusion
Standard:
investigation of the pleural fluid by an
experienced cytopathologist
Pleural effusion of tumour
origin
Standard:
thoracoscopy with talc pleurodesis for patients with free,
malignant pleural effusion recurring in a nontrapped lung
Options:
when thoracoscopy with talc pleurodesis cannot be performed,
the following treatments can be considered :
   intrapleural instillation of a talc suspension
   intrapleural instillation of bleomycin
   intrapleural instillation of tetracycline
stage IV
Figure 11

Figure 10 Management of pleural effusion with tumour origin
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The standard treatment for patients with multiple brain metastases
is 10–12 sessions of radiotherapy at a dose of 3Gy each, given in
five sessions per week (standard, level of evidence: C).
Chemotherapy can also be considered (option, level of evidence:
C). Randomised clinical trials should be undertaken to assess
which drugs are the most efficacious and to confirm results already
obtained (recommendation). Survival without CNS recurrence
should be evaluated. The evaluation of radiotherapy and its role in
relation to chemotherapy (concomitant or sequential) should be
investigated (recommendation).
EVALUATION OF TREATMENT RESPONSE
Investigations to be performed to evaluate the treatment
response
A thoracic CT scan should be performed before and after
treatment to evaluate the treatment response (standard, level of
evidence: B2).
Re-evaluation after treatment
In patients with a complete or partial response, as shown by CT
scan, the role of fibroscopy to formally assess the tumour status
should be evaluated in the setting of a clinical trial (recommenda-
tion, expert agreement).
Evaluation of extra-thoracic lesions
Liver and adrenal gland metastases should be formally assessed
prior to chemotherapy (standard). Bone metastases and pleural
effusions should not be used for treatment response evaluation
(standard). Skin metastases can be used to assess response
(option).
Principles of the treatment response evaluation
The following principles are recommended (expert agreement):
 record and classify all lesions present at the beginning of
treatment;
Non-small-cell lung cancer, stage IV
No Yes
Operable tumour and
single and operable brain
or adrenal gland
metastasis?
Performance
status?
< 2 > 2
Standards:
   chemotherapy comprising cisplatin
   ± palliative radiotherapy
Option:
chemotherapy without cisplatin in elderly patients
or those with contra-indications to cisplatin
Option:
   chemotherapy in selected patients
   palliative treatment 
   palliative radiotherapy
Standard:
excision of the metastasis 
followed by excision of the
lung tumour
Figure 11 Stage IV tumours
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preference to lesions that can be easily measured on a CT scan
 follow the WHO rules for evaluating global response;
 verify that the initial sample sites are histologically negative to
confirm a complete response;
 fibroscopy is not warranted for re-evaluation in patients with
lesions that are stable or are progressing as shown by CT scan;
 take into consideration the quality of the response in terms of
the duration of response and especially, improvement in
symptoms and quality of life.
FOLLOW-UP AFTER TREATMENT (FIGURE 12)
Follow-up should be performed with fibroscopy and CT scans
(option, expert agreement). Multicentre randomised clinical trials
should be undertaken to compare a defined follow-up strategy with
no follow-up and with different follow-up strategies. These trials
should evaluate the patients’ quality of life and the cost
effectiveness of the strategy (recommendation).
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Non-small-cell lung cancer, after curative
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Figure 12 Surveillance after treatment
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